Replies to post #265512 on Anavex Life Sciences Corp (AVXL)

[frrol]

If, not when. Experimental drug development is not remotely predictable. See the mountains of failed predictions.

And what you are describing is not patentable. What is patentable are specified novel drugs for specified applications. If our approach is successful, others will follow. We would not be able to stop them from developing an S1/mixed muscarinic agonist. What can we do? Defend our patents on 2-73, if they are infringed. And we can promote 2-73 as much as possible while challengers are under development, which should be a good 5-7 years. The impetus would be strong to challenge, and quickly.

See CAR-T cancer treatment approach as an example. Note what is patented and what is being challenges and what is being upheld. The CAR-T approach itself is brilliant, useful, and valuable, and not patented. Let alone a more esoteric "process" you propose.